Epitan receives marketing approval for Zindaclin

By Ruth Beran
Tuesday, 08 November, 2005

Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has received approval from the Therapeutic Goods Administration (TGA) for the registration of anti-acne treatment Zindaclin.

Zindaclin is a once-a-day clindamycin-based gel which Epitan's wholly-owned subsidiary Epipharm in-licensed from UK-based Pro-Strakan Pharmaceuticals (formerly Strakan) in July 2004. The product was submitted for registration from the TGA soon after.

Unhealthy Western diet could accelerate cognitive decline

An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Epitan receives marketing approval for Zindaclin

Unhealthy Western diet could accelerate cognitive decline

Cancer drug enters clinical trials based on a false mechanism

Russia insists there is "no plague case" following lab worker death

Content from other channels on our network